AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03374475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20mg
Description: Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
Study NCT03374475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40mg
Description: Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
Study NCT03374475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Study NCT03374475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Study NCT04356469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
Study NCT02012725 — intervention group
Intervention type: DRUG
Intervention: Arm 1 MRI with gadolinium
Description: Healthy volunteers will not receive gadolinium
Study NCT02309957 — intervention group
Intervention type: DEVICE
Intervention: BioMatrix CRD
Study NCT03808792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound, CT and WB-DWI/MRI
Description: Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
Study NCT00799981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A=SpeediCath Compact 7 cm and B=POBE 10 cm
Description: Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Study NCT01161238 — intervention group
Intervention type: OTHER
Intervention: Monitored for limb volume
Description: Subjects are monitored for limb volume change using bioimpedance analysis
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Call Quitline Counseling
Description: The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-Call Quitline Counseling
Description: The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
Study NCT03538938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
Study NCT03538938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch and Nicotine Lozenge
Description: The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmokefreeTXT
Description: SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SmokefreeTXT
Description: Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
Study NCT02610517 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Training
Description: All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
Study NCT02610517 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Intervention
Description: Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
Study NCT03821987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
Study NCT01170325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Study NCT01170325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT04916717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counseling
Description: Face-to-face and telephone counseling were applied to individuals in the intervention group.
Study NCT01858038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Repair - Fractional Laser treatment
Description: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
Study NCT02123719 — intervention group
Intervention type: OTHER
Intervention: Surgery
Study NCT03414944 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SMART-Brain
Description: Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy.
Study NCT01309412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
Study NCT01844037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OneShot Ablation System
Description: Renal denervation
Study NCT00353223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and behavioral psychotherapy
Description: Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
Study NCT00353223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control (AC) condition
Description: The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
Study NCT02267915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Rituximab
Description: MabThera 1400 mg solution for subcutaneous injection
Study NCT02405767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot ulcer impedance
Description: lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
Study NCT00791219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives for Treatment Engagement
Description: Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
Study NCT00791219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
Study NCT00791219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken approximately 30 minutes prior to breakfast
Study NCT00441285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: - Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
Study NCT00441285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: * Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days.
Study NCT00441285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABZ Placebo
Description: - Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
Study NCT00441285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PZQ Placebo
Description: - Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
Study NCT03995888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose monohydrate (55 g) dissolved with 500 mL of water
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina soup
Description: Semolina soup (322 g) eaten with 500 mL of water
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread
Description: Bread (122 g) eaten with 500 mL of water
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penne (fresh)
Description: Cooked penne (132 g) eaten with 500 mL of water
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penne (dry)
Description: Cooked penne (142 g) eaten with 500 mL of water
Study NCT03024983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaghetti (dry)
Description: Cooked spaghetti (142 g) eaten with 500 mL of water
Study NCT01331369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensification of Care
Description: Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
Study NCT01331369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care provided (medical and/or nurse consultation and medicines)
Study NCT02089048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
Study NCT03666442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
Study NCT00039624 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
Study NCT03800316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video Consultation
Description: Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
Study NCT04030598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered SC
Study NCT04030598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching solution administered SC
Study NCT02076620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNFα
Description: L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
Study NCT02076620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
Study NCT05996939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.
Description: Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
Study NCT01835912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
Study NCT01835912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Citrate Dihydrate
Description: Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
Study NCT02694133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smart Phone Based Assistive Speech Therapeutic System
Description: use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
Study NCT02694133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile phone-based tele rehabilitation program
Description: Mobile phone-based tele rehabilitation program
Study NCT03748134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W day 1
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m\^2 IV Q3W day 1
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
Study NCT03748134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Study NCT03889249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Stroke Thrombolytic
Study NCT03889249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Stroke Thrombolytic
Study NCT04297202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With SHR-1210 Injection
Description: 3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;
Study NCT00689338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin Intravenous Administration
Study NCT00689338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral Administration of Fluconazole
Study NCT00689338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Oral Administration of Voriconazole
Study NCT04145856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I31 probiotic
Description: I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
Study NCT04145856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: I31 probiotic combined to Alverine/Simethicone
Description: * I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)
Study NCT04145856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (maltodextrin), once daily (u.i.d)
Study NCT02464137 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
Study NCT03669601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
Study NCT03669601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside metabolic inhibitor.
Study NCT03459625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MSBR)
Description: MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
Study NCT03459625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Support Group (PE)
Description: The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.